- Hong Kong small-cap stocks showed a divergent trend recently, driven by regulatory changes and strategic adjustments.
- Biotech firms like JW Cayman Therapeutics saw a 15.4 % weekly gain after entering national medical insurance negotiations, while tech companies experienced mixed performances.
- This market fluctuation reflects small-cap enterprises' adaptive restructuring amid shifting regulatory environments and broader economic uncertainties.
- Hong Kong stocks saw a collective recovery across multiple sub-sectors driven by favorable fundamental data and capital inflows.
- Key catalysts included Everest Medicines securing a May drug approval, Shanghai Electric Wind Power winning a 1 billion yuan offshore wind order, and robust financial results from companies like Akeso and Fudan Microelectronics.
- Additional performance growth was observed in education, digital healthcare, insurance, property management, and energy sectors due to policy benefits and business recovery.